Floatz logo

Sitravatinib

Sitravatinib

Sarah GoldbergSmall moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Sitravatinib cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Sarah Goldberg
Phase 2CCC
Epirubicin
Sarah Goldberg
Phase 2CCC
Pembrolizumab
Sarah Goldberg
Phase 2CCC

Same molecule, other indications

Sitravatinib is also rated in:

nonpapillary renal cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →